• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: APOLLO ENDOSURGERY ORBERA365 INTRAGASTRIC BALLOON SYSTEM; IMPLANT, INTRAGASTRIC FOR MORBID OBESITY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

APOLLO ENDOSURGERY ORBERA365 INTRAGASTRIC BALLOON SYSTEM; IMPLANT, INTRAGASTRIC FOR MORBID OBESITY Back to Search Results
Model Number B-50012
Device Problems Deflation Problem (1149); Use of Device Problem (1670)
Patient Problem Insufficient Information (4580)
Event Date 12/04/2023
Event Type  malfunction  
Manufacturer Narrative
Block h6 impact code f8 is being used to capture the reportable event of hospitalization or prolonged hospitalization.Impact code f2202 is being used to capture the reportable event of endoscopy procedure.Device code a1401 is being used to capture the reportable event of deflation problem.
 
Event Description
It was reported to boston scientific corporation that an orbera365 intragastric balloon system was implanted on (b)(6) 2022.On december 04, 2023, the patient attended sau due to passing blue urine.The patient was discharged the same day, then on (b)(6) 2023 was re-admitted for persistent symptoms.The balloon was removed on an unknown date.There were no patient complications reported as a result of this event.The patient's condition at the conclusion of the procedure was reported to be stable.Note: it was reported that methylene blue was used when filling the orbera balloon.However, according to the instructions for use (ifu) the igb is places in the stomach and filled with sterile saline.Additional it was reported that the patient refused the planned removal on (b)(6) 2023.The patient and physician were aware that device was license for 12 months only, however the balloon was explanted on an unknown date after 12 months.The orbera365 intragastric balloon system directions for use (dfu) states "the maximum placement period for the orbera365 system is 12 months, and it must be removed at that time or earlier.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ORBERA365 INTRAGASTRIC BALLOON SYSTEM
Type of Device
IMPLANT, INTRAGASTRIC FOR MORBID OBESITY
Manufacturer (Section D)
APOLLO ENDOSURGERY
1120 s. capital of texas hwy
bldg 1 suite 300
austin TX 78746
Manufacturer (Section G)
APOLLO ENDOSURGERY COSTA RICA S.R.L
alajuela, 02
Manufacturer Contact
carole morley
300 boston scientific way
marlborough, MA 01752
5086834015
MDR Report Key19003008
MDR Text Key339250503
Report Number3005099803-2024-01264
Device Sequence Number1
Product Code LTI
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Health Professional
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 03/29/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberB-50012
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 03/06/2024
Initial Date FDA Received03/29/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-